Shares in Dr. Reddy’s Laboratories (NYSE:RDY) shot up yesterday after the U.S. Court of Appeals for the Federal Circuit vacated a previous decision that blocked the company from selling a generic verson of Indivior‘s (LON:INDV) Suboxone buprenorphine and naloxone sublingual film.
Dr. Reddy’s said it plans to resume launch activities for the product, which won FDA approvalin June.
Get the full story at our sister site, Drug Delivery Business News.
The post Dr. Reddy’s notches win for generic Suboxone sublingual film appeared first on MassDevice. (Source: Mass Device)
MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
